All Information (Except Text) for S.1322 - SALTS Act113th Congress (2013-2014)
|Sponsor:||Sen. Klobuchar, Amy [D-MN] (Introduced 07/18/2013)|
|Committees:||Senate - Judiciary|
|Latest Action:||Senate - 05/14/2014 Committee on United States Senate Caucus on International Narcotics Control. Hearings held. (All Actions)|
This bill has the status Introduced
Here are the steps for Status of Legislation:
There is 1 version of this bill. View text
Click the check-box to add or remove the section, click the text link to scroll to that section.
Titles Actions Overview All Actions Cosponsors Committees Related Bills Subjects Latest Summary All Summaries
Actions Overview (1)
|07/18/2013||Introduced in Senate|
07/18/2013 Introduced in Senate
All Actions (3)
|05/14/2014||Committee on United States Senate Caucus on International Narcotics Control. Hearings held.|
|09/25/2013||Committee on United States Senate Caucus on International Narcotics Control. Hearings held.|
|07/18/2013||Read twice and referred to the Committee on the Judiciary.|
Action By: Senate
05/14/2014 Committee on United States Senate Caucus on International Narcotics Control. Hearings held.
09/25/2013 Committee on United States Senate Caucus on International Narcotics Control. Hearings held.
07/18/2013 Read twice and referred to the Committee on the Judiciary.
|Sen. Graham, Lindsey [R-SC]*||07/18/2013|
|Sen. Feinstein, Dianne [D-CA]*||07/18/2013|
|Sen. Schumer, Charles E. [D-NY]||09/12/2013|
|Sen. Whitehouse, Sheldon [D-RI]||12/19/2013|
|Sen. Begich, Mark [D-AK]||02/27/2014|
|Committee / Subcommittee||Date||Activity||Reports|
|Senate Judiciary||07/18/2013||Referred to|
|Senate Narcotics Caucus||05/14/2014||Hearings by|
Subject — Policy Area:
One Policy Area term, which best describes an entire measure, is assigned to every public bill or resolution.
Latest Summary (1)
Introduced in Senate (07/18/2013)
Synthetic Abuse and Labeling of Toxic Substances Act of 2013 or the SALTS Act - Amends the Controlled Substances Act to provide that, in determining whether a controlled substance analogue was intended for human consumption, the following factors may be considered: (1) the marketing, advertising, and labeling of the substance; (2) the known efficacy or usefulness of the substance for the marketed, advertised, or labeled purpose; (3) the difference between the price at which the substance is sold and the price at which the substance it is purported to be or advertised as is normally sold; (4) the diversion of the substance from legitimate channels and the clandestine importation, manufacture, or distribution of the substance; and (5) whether the defendant knew or should have known that the substance was intended to be consumed by injection, inhalation, ingestion, or any other immediate means.
Declares that evidence that a substance was not marketed, advertised, or labeled for human consumption shall not by itself be sufficient to establish that the substance was not intended for human consumption.